Comparison of Butorphanol and Tramadol Associated Patient-Controlled Analgesia (PCA) After Hysterectomy
Completed
HRSA/Maternal and Child Health Bureau
Phase 4
2007-01-01
Intravenous patient-controlled analgesia (PCA) is a popular technique for postoperative pain
management. Although several drugs are recognized as effective therapeutic options, optimal
selection of drugs in hysterectomy patients underwent different anesthesia treatments remains
unknown explicitly. The investigators hypothesized that butorphanol and tramadol can produce
different analgesic effects with intravenous PCA after abdominal hysterectomy.
Comparison of Butorphanol and Tramadol Associated Patient-Controlled Analgesia (PCA) After Hysterectomy
Completed
Nanjing Medical University
Phase 4
2007-01-01
Intravenous patient-controlled analgesia (PCA) is a popular technique for postoperative pain
management. Although several drugs are recognized as effective therapeutic options, optimal
selection of drugs in hysterectomy patients underwent different anesthesia treatments remains
unknown explicitly. The investigators hypothesized that butorphanol and tramadol can produce
different analgesic effects with intravenous PCA after abdominal hysterectomy.
Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia
Completed
Nanjing Medical University
Phase 4
2008-07-01
Fast awakening from anesthesia is one of the major characteristics of remifentanil-associated
anesthetic induction and maintenance, whereas corresponding pain during awakening influences
patient's rehabilitation strongly. In addition, such early postoperative pain results in
significant stress responses, which displays as further release of stress hormones such as
cortisol and β-endorphin as well. How to prevent such acute pain resulting from
remifentanil's fast metabolism endows clinical significance. This study is designed to
compare the analgesic efficacy of fentanyl, sufentanil and butorphanol delivered after
gynecological laparoscopic surgeries that underwent remifentanil induction and maintenance,
and investigate corresponding influence on the levels of blood cortisol and β-endorphin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
